← Dashboard

Compliance Alert: Trelegy Ellipta

Configure Methodology
79
Lower Risk

Trelegy Ellipta scores 79/100 (Lower Risk) based on analysis of 60s promotional content. 2 enforcement patterns detected across Visual Distraction — “Family & Social Scenes” identified at 44.6s, previously cited in Jardiance (x3), Contrave, Qulipta. Weakest dimension: Visual Distraction at 68/100.

Trelegy Ellipta | GSK | DTC Broadcast
Mar 7, 2026

Patterns Detected (2)

Matched against 14 enforcement patterns from 42 FDA letters

Visual Distraction
Family & Social Scenes
Risk information must be presented in a clear, conspicuous, and neutral manner without distracting visuals
68
44.6s – 52.1s
FDA Precedent: Jardiance (x3), Contrave, Qulipta, Calquence, Austedo (x2) 21 CFR 202.1(e)(1)
Visual Distraction
Daily Activities
Risk information must be presented in a clear, conspicuous, and neutral manner without distracting visuals
68
37.0s – 44.6s
FDA Precedent: Contrave, Velsipity, Qulipta, Fasenra (salsa) 21 CFR 202.1(e)(1)
79
Master
68
Visual
30%
79
Efficacy
25%
83
Fair Balance
20%
93
Adeq Prov
15%
--
Lifecycle
10%
Safety Information Window
Risk disclosure: 31.4s – 55.7s (24.2s of 60.1s total — 40.3% of ad)
37.0s — Daily Activities
44.6s — Family Social
0s60s

Visual Evidence (2 clips)

37.0s – 44.6s Daily Activities
44.6s – 52.1s Family Social

Recommendations

low
Continue routine monitoring. No immediate MLR action required based on current analysis.

Powered by cQuenced